Predictive factors for neurocognitive function and quality of life after surgical treatment for cushing’s disease and acromegaly

Journal of Endocrinological Investigation

Volumn 34, Issue 7, 2011, Pages e168-e177

  Psaras, T ^a   Milian, M ^a   Hattermann, V ^a   Will, B E ^a   Tatagiba, M ^a   Honegger, J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Acromegaly; Cushing s disease; Neurocognition; Quality of life

Indexed keywords

DEXAMETHASONE; GROWTH HORMONE; HYDROCORTISONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGE; ANXIETY DISORDER; ARTICLE; ATTENTION; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CUSHING DISEASE; DEMOGRAPHY; DEPRESSION; EDUCATIONAL STATUS; FEMALE; HEALTH STATUS; HOSTILITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OBSESSIVE COMPULSIVE DISORDER; OVERNIGHT DEXAMETHASONE SUPPRESSION TEST; PARANOIA; PHOBIA; POSTOPERATIVE PERIOD; PREDICTION; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; REMISSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOMATIZATION; TRANSSPHENOIDAL HYPOPHYSECTOMY; AGED; COGNITION; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE;

ACROMEGALY; ADULT; AGED; COGNITION; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PITUITARY ACTH HYPERSECRETION; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 83155182577     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7333     Document Type: Article

References (61)

1. Yanovski JA, Cutler GB Jr. Glucocorticoid action and the clinical feature of Cushing’s syndrome. Endocrinol Metab Clin North Am 1994, 23: 487-509.
2. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing’s syndrome after correction or hypercortisolism. J Clin Endocrinol Metab 1997, 82: 912-9.
3. van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 2005, 90: 279-86.
4. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2007, 92: 1743-7.
5. Furman K, Ezzat S. Psychological features of acromegaly. Psychother Psychosom 1998, 67: 147-53.
6. Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary 2002, 5: 7-9.
7. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004, 89: 5369-76.
8. Guinan EM, Lowy C, Stanhope N, Lewis PD, Kopelman MD. Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatr 1998, 65: 870-6.
9. Heald A, Parr C, Gibson C, O’driscoll K, Fowler H. A cross-sectional study to investigate long-term cognitive function in people with treated pituitary Cushing’s disease. Exp Clin Endocrinol Diabetes 2006, 114: 490-7.
10. Hook JN, Giordani B, Schteingart DE, et al. Patterns of cognitive change over time and relationship to age following successful treatment of Cushing`s disease. J Int Neuropsychol Soc 2007, 13: 21-9.
11. Martignoni E, Costa A, Sinforiani E, et al. The brain as a target for adrenalcortical steroids: Cognitive implications. Psychoneuroendo-crinology 1992, 17: 343-54.
12. Mauri M, Sinforiani E, Bono G, et al. Memory impairment in Cushing’s disease. Acta Neurol Scand 1993, 87: 52-5.
13. Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing’s syndrome and depression – a prospective study of 26 patients. Br J Psychiatry 1983, 142: 16-9.
14. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol 1996, 45: 715-20.
15. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006, 83: 224-9.
16. Paisley AN, Rowles SV, Roberts ME, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol 2007, 67: 358-62.
17. Sardella C, Lombardi M, Rossi G, et al. Short-and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest 2010, 33: 20-5.
18. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire. J Clin Endocrinol Metab 2005, 90: 3337-41.
19. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 2006, 155: 831-7.
20. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adreno-corticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93: 2454-62.
21. Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509-17.
22. th ed). Göttingen: Hogrefe, 2002.
23. Wechsler D. Wechsler Adult Intelligence Scale (3rd ed). San Antonio: The Psychological Corporation 1997.
24. nd ed). Göttingen: Hogrefe, 2007.
25. nd ed). Göttingen: Hogrefe, 1987.
26. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Conceptual framework and item selection. Med Care 1992, 30: 473-83.
27. Derogatis LR. SCL-90-R: administration, scoring and procedures manual. Towson: Clinical Psychiatric Association, 1983.
28. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002, 57: 251-8.
29. Badia X, Webb SM, Prieto L, Lara N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2004, 2: 13.
30. Grattan-Smith PJ, Morris JG, Shores EA, Batchelor J, Sparks RS. Neuropsychological abnormalities in patients with pituitary tumours. Acta Neurol Scand 1992, 86: 626-31.
31. Peace KA, Orme SM, Thompson AR, Padayatty S, Ellis AW, Belchetz PE. Cognitive dysfunction in patients treated for pituitary tumours. J Clin Exp Neuropsychol 1997, 19: 1-6.
32. Starkman MN, Giordani B, Berent S, Schork MA, Schteingart DE. Elevated Cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosom Med 2001, 63: 985-93.
33. Bourdeau I, Bard C, Noël B, et al. Loss of brain volume in endogenous Cushing’s syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002, 87: 1949-54.
34. Page RC, Hammersley MS, Burke CW, Wass JA. An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 1997, 46: 401-6.
35. Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary 2003, 6: 81-7.
36. Heald AH, Ghosh S, Bray S, Gibson C, et al. Long-term negative impact of quality of life in patients with successfully treated Cushing’s disease. Clin Endocrinol 2004, 61: 458-65.
37. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing’s syndrome despite initial im- provement after surgical remission. J Clin Endocrinol Metab 2006, 91: 447-53.
38. Dekkers OM, Biermasz NR, Smit JW, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol 2006, 154: 483-9.
39. Luria AR. The neuropsychology of memory. New York: John Wiley, 1976.
40. nd ed. Oxford: Blackwell 1987.
41. Freedman L, McFadden L. Diencephalic amnesia secondary to craniopharyngioma. J Int Neuropsychol Soc 1995, 1: 170.
42. Meyers CA. Neurobehavioral functioning of adults with pituitary disease. Psychother Psychosom 1998, 67: 168-72.
43. Whelan TB, Schteingart DE, Starkman MN, Smith A. Neuropsychological deficits in Cushing’s syndrome. J Nerv Ment Dis 1980, 168: 753-7.
44. Starkman MN, Schteingart DE. Neuropsychiatric manifestifications of patients with Cushing´s syndrome. Arch Intern Med 1981, 141: 215-9.
45. Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing’s syndrome: ‘atypical’ or melancholic features. Clin Endocrinol 1995, 43: 433-42.
46. Peace KA, Orme SM, Padayatty SJ, Godfrey HP, Belchetz PE. Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication. Clin Endocrinol 1998, 49: 391-6.
47. Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing’s syndrome. Psychoneuro-endocrinology 2002, 27: 367-83.
48. Webb SM, Badia X, Barahona MJ, et al. Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 2008, 158: 623-30.
49. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992, 32: 756-65.
50. Simmons NE, Do HM, Lipper, MH, Laws ER Jr. Cerebral atrophy in Cushing’s disease. Surg Neurol 2000, 53: 72-6.
51. nd Annual Meeting of the Endocrine Society, Toronto, p. 466 (abstract)
52. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88: 5593-602.
53. De Kloet ER, Oitzl MS, Joëls M. Stress and cognition: are corti-costeroids good or bad guys? Trends Neurosci 1999, 22: 422-6.
54. Sandi C, Rose SPR. Corticosterone enhances long-term memory in one day-old chicks trained in a weak passive avoidance learning paradigm. Brain Res 1994, 647: 106-12.
55. Oitzl MS, Fluttert M, De Kloet ER. The effect of corticosterone on reactivity to spatial novelty is mediated by central mineralcorti-costeroid receptors. Eur J Neurosci 1994, 6: 1072-9.
56. Pikkarainen L, Sane T, Reunanen A. The survival and well-being of patients treated for Cushing’s syndrome. J Intern Med 1999, 245: 463-8.
57. Grabner P, Hauer-Jensen M, Jervell J, Flatmark A. Long-term results of treatment of Cushing’s disease by adrenalectomy. Eur J Surg 1991, 157: 461-4.
58. Gotch PM. Cushing’s syndrome from the patient’s perspective. Endocrinol Metab Clin North Am 1994, 23: 607-17.
59. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2: 29-41.
60. Psaras T, Milian M, Hattermann V, Gallwitz B, Freiman T, Honegger J. Aftercare in patients with Cushing’s disease and acromegaly – is there room for improvement? Acta Neurochir (Wien) 2010, 152: 271-9.
61. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005, 95: 2731-9.